A judge has ordered federal prosecutors to drop a criminal tax fraud case against a medical researcher, finding an ATO officer lied and tampered with evidence during the probe.
The Australian Securities and Investments Commission has approved Cboe’s application to list companies on its platform, in direct competition with market operators, including the Australian Securities Exchange.
Engineering firm WSP may seek to permanently stay a new suit by Canberra builder Morris Construction that claims it should be on the hook for engineering and design failures by a subsidiary, the latest fight between the parties over a troubled Kingston development.
Engineer Monadelphous has lost a fight that will affect its ability to run a limitations defence in a suit over alleged defects in a sewage plant upgrade on the Sunshine Coast.
A judge has questioned whether an investor in failed Banksia Securities can bring a case against a court-appointed receiver over his support for a class action settlement later found to involve deception by a team of lawyers.
The receiver for Banksia Securities — the failed lender at the centre of a scandal-ridden class action — has argued a new case accusing him of serious misconduct is vexatious and wants a court to release him from the claims.
A judge has declined a creditor’s bid to wind up Victorian builder Roberts Construction Group, finding that the application relied on a “very modest” debt and involved a solicitor’s email “cast in threatening terms”.
A judge has allowed a class action over Isuzus that allegedly contained emissions cheat devices to send an opt out notice to group members that includes a warning that if they sell their cars, they may “lose some or all of the money” they could receive in any settlement.
The Australian Securities and Investments Commission has accepted court-enforceable undertakings from Hall Chadwick NSW and three of its auditors after finding the firm’s systems failed to detect breaches of auditor rotation requirements.
Pharmaceutical giant Johnson & Johnson has denied knowingly selling alleged ineffective medications under its Benadryl, Sudafed and Codral brands, saying research indicated the phenylephrine-containing products worked.